IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.310
AS - Asia 9.192
EU - Europa 3.510
SA - Sud America 2.079
AF - Africa 192
Continente sconosciuto - Info sul continente non disponibili 43
OC - Oceania 13
Totale 30.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.987
SG - Singapore 5.661
BR - Brasile 1.736
CN - Cina 1.581
VN - Vietnam 817
FI - Finlandia 748
IT - Italia 590
IE - Irlanda 511
DE - Germania 430
FR - Francia 321
IN - India 270
GB - Regno Unito 223
NL - Olanda 205
HK - Hong Kong 204
CA - Canada 148
AR - Argentina 131
BD - Bangladesh 120
SE - Svezia 93
MX - Messico 80
IQ - Iraq 71
PL - Polonia 62
TR - Turchia 62
BE - Belgio 57
EC - Ecuador 57
RU - Federazione Russa 56
ZA - Sudafrica 54
ID - Indonesia 53
ES - Italia 46
JP - Giappone 46
CO - Colombia 41
UA - Ucraina 37
MY - Malesia 36
PK - Pakistan 31
CL - Cile 28
AE - Emirati Arabi Uniti 27
MA - Marocco 27
VE - Venezuela 26
SA - Arabia Saudita 25
UZ - Uzbekistan 25
PY - Paraguay 22
NG - Nigeria 20
PH - Filippine 20
JM - Giamaica 19
KE - Kenya 19
TN - Tunisia 17
CZ - Repubblica Ceca 16
DO - Repubblica Dominicana 16
EG - Egitto 16
IL - Israele 16
LT - Lituania 16
PA - Panama 15
PE - Perù 15
UY - Uruguay 15
JO - Giordania 14
DZ - Algeria 13
AZ - Azerbaigian 12
KZ - Kazakistan 12
NP - Nepal 12
LB - Libano 10
AL - Albania 9
AT - Austria 9
NI - Nicaragua 9
TH - Thailandia 9
AU - Australia 8
PS - Palestinian Territory 8
CR - Costa Rica 7
GR - Grecia 7
LV - Lettonia 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
BO - Bolivia 6
HN - Honduras 6
KR - Corea 6
RO - Romania 6
RS - Serbia 6
AO - Angola 5
BY - Bielorussia 5
CH - Svizzera 5
KG - Kirghizistan 5
LU - Lussemburgo 5
NO - Norvegia 5
SN - Senegal 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
GE - Georgia 4
HR - Croazia 4
OM - Oman 4
PR - Porto Rico 4
XK - ???statistics.table.value.countryCode.XK??? 4
AM - Armenia 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GT - Guatemala 3
IR - Iran 3
KH - Cambogia 3
SV - El Salvador 3
Totale 30.256
Salva come PNG Salva come JPEG
Città #
Chandler 2.264
Singapore 2.167
Ashburn 1.787
San Jose 1.578
The Dalles 1.004
Helsinki 740
New York 729
Shanghai 684
Council Bluffs 554
Dublin 509
Dallas 466
Princeton 461
Lawrence 460
Boardman 445
Los Angeles 383
Paris 278
Ho Chi Minh City 270
Santa Clara 221
Beijing 208
Milan 197
Hong Kong 189
Amsterdam 182
Hanoi 174
São Paulo 148
Pune 142
Buffalo 121
Falkenstein 119
London 118
Rome 99
Phoenix 94
Seattle 76
Rio de Janeiro 68
Assago 58
Brussels 56
Brooklyn 52
Munich 50
Warsaw 50
Chicago 45
Haiphong 44
Belo Horizonte 42
Wilmington 42
Frankfurt am Main 41
Montreal 38
Orem 37
Boston 36
Da Nang 36
Curitiba 35
Tokyo 35
Chennai 34
Mexico City 34
Johannesburg 31
Toronto 31
Charlotte 30
San Francisco 30
Stockholm 30
Brasília 28
Porto Alegre 27
Baghdad 26
Atlanta 24
Dhaka 24
Berlin 23
Kuala Lumpur 23
Columbus 22
Denver 21
Guayaquil 21
Istanbul 21
Tashkent 21
Moscow 20
Biên Hòa 19
Guangzhou 18
Campinas 17
Guarulhos 17
Kingston 17
Benin City 16
Hải Dương 16
Figino 15
Miami 15
Quito 15
Montevideo 14
Naples 14
Pasadena 14
San Mateo 14
Washington 14
Amman 13
Ankara 13
Bogotá 13
Nairobi 13
Ninh Bình 13
Ribeirão Preto 13
Borås 12
Clifton 12
Erbil 12
Jakarta 12
Manaus 12
Manchester 12
Panama City 12
Santiago 12
Thái Nguyên 12
Turin 12
Baku 11
Totale 18.597
Salva come PNG Salva come JPEG
Nome #
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 145
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 123
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 117
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics 115
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 110
Reduced expression of the rock inhibitor rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells 106
Mesothelioma. From research to clinical practice 105
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 104
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 103
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 102
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 102
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 97
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 96
The unique biological features of the marine product Yondelis? (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring 96
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 93
"The Art of Successful Publication" ECCO 13 workshop report 92
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 92
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 92
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 91
A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging 91
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 91
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 89
Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to alpha(1)-acid glycoprotein plasma levels 88
A novel taxane active against an orthotopically growing human glioma xenograft 88
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 88
How Medicines are Born. The Imperfect Science of Drugs 88
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 87
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 87
A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia 87
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 86
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells 86
The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism 84
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 83
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 83
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 82
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 82
Interferon-beta can induce progesterone receptors in human endometrial adenocarcinoma 82
Sequence-specific DNA alkylation of novel tallimustine derivatives 80
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 80
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 80
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 80
Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue 80
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 80
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 79
Mechanisms of resistance to alkylating agents 78
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 78
A comprehensive investigation of histotype-specific microRNA and their variants in stage I epithelial ovarian cancers 78
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 77
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 77
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 77
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 77
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 77
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 77
A FILTER INCUBATION METHOD FOR THE DETERMINATION OF POTENTIALLY CROSSLINKABLE SITES IN DNA IN MAMMALIAN-CELLS 77
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 77
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters 76
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 76
Unique features of the mode of action of ET-743 74
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 74
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 74
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 74
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study 74
Targeting triple negative breast cancer: Is p53 the answer? 74
Are we close to the clinical development of novel drugs targeting telomeres and telomerase? 74
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 73
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 73
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy 73
The potential impact of marine compounds in the era of targeting therapies 72
Paclitaxel induces significant changes in epidoxorubicin distribution in mice 72
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 72
Trabectedin therapy for sarcomas 72
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 72
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging 72
Pharmacological study on PEG-Asparaginase used in front-line treatment of children with acute lymphoblastic leukemia 72
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 72
Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles 72
New drugs from the sea 72
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice 71
DECREASED CYTOTOXIC EFFECTS OF DOXORUBICIN IN A HUMAN OVARIAN CANCER-CELL LINE EXPRESSING WILD-TYPE P53 AND WAF1/CIP1 GENES 71
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 71
Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours 71
AN OPEN-LABEL, RANDOMIZED PHASE II STUDY ON TRABECTEDIN AND BEVACIZUMAB WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE (PPS) OVARIAN CANCER 71
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 71
High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol (R)) in human plasma 71
Modulation of gene transcription by natural products - A viable anticancer strategy 71
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 71
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections 70
Genetic Instability Influences Drug Response in Cancer Cells 70
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 70
Role of homologous recombination in trabectedin-induced DNA damage 70
Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma 70
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 70
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 70
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect 70
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 69
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer 69
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 69
L-asparagine-depletion: Another opinion - Response 69
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 69
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 69
Totale 8.164
Salva come PNG Salva come JPEG
Categoria #
all - tutte 197.661
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 197.661
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022242 0 4 0 7 1 0 0 7 19 5 67 132
2022/20236.459 1.028 151 587 747 428 615 5 690 1.151 575 412 70
2023/20243.814 333 311 940 283 106 679 113 195 39 176 366 273
2024/20254.849 121 16 21 98 128 615 255 271 1.022 1.228 579 495
2025/202613.612 2.014 895 618 1.257 390 687 4.140 544 737 843 537 950
2026/20271.296 550 746 0 0 0 0 0 0 0 0 0 0
Totale 30.339